JP2017533895A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533895A5 JP2017533895A5 JP2017517315A JP2017517315A JP2017533895A5 JP 2017533895 A5 JP2017533895 A5 JP 2017533895A5 JP 2017517315 A JP2017517315 A JP 2017517315A JP 2017517315 A JP2017517315 A JP 2017517315A JP 2017533895 A5 JP2017533895 A5 JP 2017533895A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- reaction
- pharmaceutically acceptable
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- 238000006243 chemical reaction Methods 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 238000002360 preparation method Methods 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 230000000155 isotopic effect Effects 0.000 claims 5
- -1 4-((4- (3- (5- (tert-butyl) -2-methoxy-3- (methylsulfonamido) phenyl) ureido) naphthalen-1-yl) oxy) pyridin-2-yl Chemical group 0.000 claims 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 3
- 206010013774 Dry eye Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 208000005494 xerophthalmia Diseases 0.000 claims 3
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010011017 Corneal graft rejection Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 201000007407 panuveitis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 238000006462 rearrangement reaction Methods 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 0 Nc1ccc2C(O)=*c2c1 Chemical compound Nc1ccc2C(O)=*c2c1 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1417344.7 | 2014-10-01 | ||
| GBGB1417344.7A GB201417344D0 (en) | 2014-10-01 | 2014-10-01 | New compounds |
| GB1510694.1 | 2015-06-18 | ||
| GBGB1510694.1A GB201510694D0 (en) | 2015-06-18 | 2015-06-18 | New compounds |
| PCT/GB2015/052877 WO2016051188A1 (en) | 2014-10-01 | 2015-10-01 | 4-(4-(4-phenylureido-naphthalen-1-yl)oxy-pyridin-2-yl)amino-benzoic acid derivative as p38 kinase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533895A JP2017533895A (ja) | 2017-11-16 |
| JP2017533895A5 true JP2017533895A5 (enExample) | 2018-11-08 |
| JP6662863B2 JP6662863B2 (ja) | 2020-03-11 |
Family
ID=54337298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517316A Expired - Fee Related JP6608918B2 (ja) | 2014-10-01 | 2015-10-01 | Ｐ３８キナーゼ阻害剤としてのジアリール尿素誘導体 |
| JP2017517315A Expired - Fee Related JP6662863B2 (ja) | 2014-10-01 | 2015-10-01 | Ｐ３８キナーゼ阻害剤としての４−（４−（４−フェニルウレイドナフタレン−１−イル）オキシピリジン−２−イル）アミノ安息香酸誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517316A Expired - Fee Related JP6608918B2 (ja) | 2014-10-01 | 2015-10-01 | Ｐ３８キナーゼ阻害剤としてのジアリール尿素誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US9751837B2 (enExample) |
| EP (2) | EP3201179A1 (enExample) |
| JP (2) | JP6608918B2 (enExample) |
| KR (2) | KR20170063783A (enExample) |
| CN (2) | CN107001274A (enExample) |
| AU (2) | AU2015326614B2 (enExample) |
| BR (2) | BR112017006073A2 (enExample) |
| CA (1) | CA2961870A1 (enExample) |
| EA (2) | EA035478B1 (enExample) |
| MA (2) | MA40774A (enExample) |
| MX (2) | MX373658B (enExample) |
| WO (2) | WO2016051188A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008337286B2 (en) | 2007-12-19 | 2014-08-07 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| JP5760010B2 (ja) | 2010-02-01 | 2015-08-05 | キャンサー・リサーチ・テクノロジー・リミテッド | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 |
| PE20142355A1 (es) | 2011-10-03 | 2015-01-10 | Respivert Ltd | 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)ureas como inhibidores de proteinas cinasas activadas por mitogeno p38 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| US9771353B2 (en) * | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| BR112015024671A2 (pt) * | 2013-04-02 | 2017-07-18 | Respivert Ltd | derivados de ureia úteis como inibidores de quinase |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2015092423A1 (en) * | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| PT3357919T (pt) | 2014-02-14 | 2020-02-20 | Respivert Ltd | Compostos heterocíclicos aromáticos como compostos antiinflamatórios |
| MA40774A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| AU2017245888B2 (en) * | 2016-04-06 | 2021-05-13 | Oxular Acquisitions Limited | Kinase inhibitors |
| WO2019071144A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| MX2021006731A (es) | 2018-12-07 | 2021-09-23 | Univ Maryland | Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico. |
| WO2021022163A2 (en) | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12528825B2 (en) * | 2020-01-29 | 2026-01-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2022010764A1 (en) * | 2020-07-06 | 2022-01-13 | Vivtex Corporation | Mucopenetrating formulations |
| MX2023009249A (es) * | 2021-02-08 | 2023-10-23 | Bausch Health Ireland Ltd | Método para prevenir, tratar o mejorar la colitis ulcerosa. |
| JP7659650B2 (ja) * | 2021-03-23 | 2025-04-09 | ジーニー ライフサイエンシズ インコーポレイテッド | 置換ナフチルｐ３８アルファマイトジェン活性化プロテインキナーゼ阻害剤 |
| EP4705280A1 (en) * | 2023-05-02 | 2026-03-11 | Purdue Research Foundation | Diaryl urea-based compounds and related compositions and methods of use in the treatment of diabetes mellitus and neurodegenerative disease |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080763A (en) | 1997-11-03 | 2000-06-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds and their use as anti-inflammatory agents |
| CA2359244C (en) * | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| HUP0202248A3 (en) | 1999-03-12 | 2006-06-28 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents |
| MXPA02000314A (es) | 1999-07-09 | 2004-06-22 | Boehringer Ingelheim Pharma | Proceso novedoso para la sintesis de compuestos de urea substituidos con heteroarilo. |
| MXPA02004879A (es) | 1999-11-16 | 2002-08-30 | Boehringer Ingelheim Pharma | Derivados de urea como agentes antiinflamatorios. |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| EP1415987B1 (en) * | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| MXPA03009361A (es) | 2001-04-13 | 2004-01-29 | Boehringer Ingelheim Pharma | Compuestos de urea utilies como agentes anti-inflamatorios. |
| WO2002083628A1 (en) * | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused compounds |
| WO2002092576A1 (en) | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
| EP1395561A1 (en) | 2001-05-25 | 2004-03-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
| EP1408950B1 (en) | 2001-07-11 | 2007-04-25 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of treating cytokine mediated diseases |
| WO2003068223A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
| EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
| US7041669B2 (en) | 2002-02-25 | 2006-05-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-benzofused urea compounds useful in treating cytokine mediated diseases |
| TW200406374A (en) * | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| JP2006504667A (ja) | 2002-08-08 | 2006-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 炎症過程に関与するサイトカインの抑制剤としてのフッ素化フェニル−ナフタレニル−尿素化合物 |
| WO2004113352A1 (en) | 2003-06-19 | 2004-12-29 | Amedis Pharmaceuticals Ltd. | Silylated heterocyclylurea derivatives as cytokine-inhibitors |
| WO2005005396A1 (en) | 2003-06-30 | 2005-01-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Process of making di-aryl urea compounds |
| US20050148555A1 (en) | 2003-08-22 | 2005-07-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating COPD and pulmonary hypertension |
| MXPA06002853A (es) | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
| WO2005044825A1 (en) | 2003-10-21 | 2005-05-19 | Amedis Pharmaceuticals Ltd. | Silicon compounds and their use |
| TW200529849A (en) * | 2003-11-28 | 2005-09-16 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
| GB0327734D0 (en) * | 2003-11-28 | 2003-12-31 | Novartis Ag | Organic compounds |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| TW200740820A (en) | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
| AR056582A1 (es) | 2005-10-28 | 2007-10-10 | Lilly Co Eli | COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE |
| US7790756B2 (en) * | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| KR20110070887A (ko) | 2008-10-02 | 2011-06-24 | 레스피버트 리미티드 | Ｐ38 엠에이피 키나제 억제제 |
| JP5670912B2 (ja) | 2008-12-11 | 2015-02-18 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| BRPI1010937A2 (pt) * | 2009-05-21 | 2019-09-24 | Astrazeneca Ab | composto, uso de um composto, e, método para tratar câncer |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| EP2556068B1 (en) | 2010-04-08 | 2019-01-23 | Respivert Limited | P38 map kinase inhibitors |
| EP2556067B1 (en) | 2010-04-08 | 2016-02-24 | Respivert Limited | Pyrazolyl ureas as p38 map kinase inhibitors |
| EP3039996B1 (en) | 2010-05-11 | 2024-04-10 | Breville Pty Limited | Improved espresso machine method and apparatus |
| US8933228B2 (en) | 2010-06-17 | 2015-01-13 | Respivert, Ltd. | Respiratory formulations and compounds for use therein |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| PE20142355A1 (es) | 2011-10-03 | 2015-01-10 | Respivert Ltd | 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)ureas como inhibidores de proteinas cinasas activadas por mitogeno p38 |
| ES2612259T3 (es) | 2011-12-09 | 2017-05-16 | Chiesi Farmaceutici S.P.A. | Inhibidores de cinasa |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| BR112015024671A2 (pt) * | 2013-04-02 | 2017-07-18 | Respivert Ltd | derivados de ureia úteis como inibidores de quinase |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| WO2015092423A1 (en) * | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| EP3102283B1 (en) * | 2014-02-05 | 2018-02-28 | Boston Scientific Neuromodulation Corporation | System for delivering modulated sub-threshold therapy to a patient |
| PT3357919T (pt) | 2014-02-14 | 2020-02-20 | Respivert Ltd | Compostos heterocíclicos aromáticos como compostos antiinflamatórios |
| US20170209445A1 (en) | 2014-10-01 | 2017-07-27 | Respivert Limited | Kinase inhibitors |
| MA40774A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
-
2015
- 2015-09-30 MA MA040774A patent/MA40774A/fr unknown
- 2015-09-30 MA MA040775A patent/MA40775A/fr unknown
- 2015-10-01 BR BR112017006073A patent/BR112017006073A2/pt not_active Application Discontinuation
- 2015-10-01 MX MX2017004129A patent/MX373658B/es active IP Right Grant
- 2015-10-01 EP EP15782017.6A patent/EP3201179A1/en not_active Withdrawn
- 2015-10-01 BR BR112017005531A patent/BR112017005531A2/pt not_active Application Discontinuation
- 2015-10-01 WO PCT/GB2015/052877 patent/WO2016051188A1/en not_active Ceased
- 2015-10-01 KR KR1020177010961A patent/KR20170063783A/ko not_active Withdrawn
- 2015-10-01 CA CA2961870A patent/CA2961870A1/en active Pending
- 2015-10-01 AU AU2015326614A patent/AU2015326614B2/en not_active Ceased
- 2015-10-01 KR KR1020177011685A patent/KR20170057445A/ko not_active Ceased
- 2015-10-01 EA EA201790658A patent/EA035478B1/ru not_active IP Right Cessation
- 2015-10-01 EP EP15782018.4A patent/EP3201180A1/en not_active Withdrawn
- 2015-10-01 CN CN201580053462.2A patent/CN107001274A/zh active Pending
- 2015-10-01 JP JP2017517316A patent/JP6608918B2/ja not_active Expired - Fee Related
- 2015-10-01 US US14/872,527 patent/US9751837B2/en not_active Expired - Fee Related
- 2015-10-01 MX MX2017004128A patent/MX2017004128A/es unknown
- 2015-10-01 CN CN201580053439.3A patent/CN106999478A/zh active Pending
- 2015-10-01 JP JP2017517315A patent/JP6662863B2/ja not_active Expired - Fee Related
- 2015-10-01 AU AU2015326543A patent/AU2015326543B2/en not_active Ceased
- 2015-10-01 EA EA201790660A patent/EA032694B1/ru not_active IP Right Cessation
- 2015-10-01 WO PCT/GB2015/052876 patent/WO2016051187A1/en not_active Ceased
- 2015-10-01 US US14/872,807 patent/US9499486B2/en not_active Expired - Fee Related
-
2016
- 2016-10-12 US US15/291,359 patent/US9822076B2/en not_active Expired - Fee Related
-
2017
- 2017-05-24 US US15/604,258 patent/US10125100B2/en active Active
-
2018
- 2018-07-13 US US16/035,502 patent/US10392346B2/en active Active
-
2019
- 2019-07-10 US US16/508,253 patent/US10941115B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3752495B1 (en) | Pyridine derivatives and their use for treating hiv infection | |
| JP6608918B2 (ja) | Ｐ３８キナーゼ阻害剤としてのジアリール尿素誘導体 | |
| JP2017535525A5 (enExample) | ||
| JP2013545817A5 (enExample) | ||
| JP2019517463A5 (enExample) | ||
| JP2013545816A5 (enExample) | ||
| JP2017502033A5 (enExample) | ||
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2017536395A5 (enExample) | ||
| JP2012530713A5 (enExample) | ||
| TW201034669A (en) | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors | |
| JP2017141281A5 (ja) | オキシトシン／バソプレッシンＶ１ａレセプターのアンタゴニストとしてのピロリジン誘導体を含有する医薬組成物 | |
| JP2022505637A5 (enExample) | ||
| TW200304824A (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
| JP2019505529A5 (enExample) | ||
| JP2018529714A (ja) | Ｈｉｖの処置のための化合物および組合せ物 | |
| JP2022526604A5 (enExample) | ||
| JP2020516697A (ja) | 核受容体の効能剤であるイソオキサゾール誘導体及びその用途 | |
| TWI694986B (zh) | 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途 | |
| JP2019514861A5 (enExample) | ||
| EP4038061A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| JP2013508385A5 (enExample) | ||
| IL296182A (en) | Inhibitors of human immunodeficiency virus replication | |
| KR20200041915A (ko) | 신규 테트라졸 화합물 및 결핵의 치료에서의 그의 용도 | |
| EP3049406A1 (de) | Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen |